liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Safety and efficacy of drug-eluting vs. bare metal stents in patients with diabetes mellitus: long-term follow-up in the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)
Linköping University, Department of Medicine and Health Sciences, Cardiology . Linköping University, Faculty of Health Sciences. Östergötlands Läns Landsting, Heart Centre, Department of Cardiology.
Uppsala Clinical Research Centre.
Uppsala Clinical Research Centre.
Department of Cardiology, Orebro, Sweden .
Show others and affiliations
2010 (English)In: EUROPEAN HEART JOURNAL, ISSN 0195-668X, Vol. 31, no 2, 177-186 p.Article in journal (Refereed) Published
Abstract [en]

Patients with diabetes mellitus have more extensive coronary artery disease, more disease progression, and restenosis. The use of drug-eluting stents (DES) in these patients is widespread, despite uncertain long-term safety and efficacy. All consecutive patients with diabetes mellitus in Sweden who underwent percutaneous coronary intervention were entered into the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) during 2003-06 with complete follow-up for 1-4 years (median 2.5). Patients who received at least one DES (n = 4754) were compared with those who received only bare metal stents (BMS) (n = 4956) at the index procedure. Combined outcome of death or myocardial infarction (MI) showed no difference for DES vs. BMS, relative risk (RR), 0.91 [95% confidence interval (CI), 0.77-1.06]. Myocardial infarction was significantly less common with DES in patients who received only one stent RR, 0.80 (95% CI, 0.66-0.96). The restenosis rate was 50% lower in DES-treated patients RR, 0.50 (95% CI, 0.35-0.70) and was associated with a higher adjusted RR of MI, RR, 5.03 (95% CI, 4.25-5.97). DES was associated with reduced restenosis rates in all subgroups of diabetic patients with the greatest benefit in stent diameters andlt; 3 mm or stent length andgt; 20 mm. The number of lesions treated with DES to prevent one restenosis ranged from 11 to 47 in various subgroups. This real-life registry study shows that restenosis was halved by DES in diabetic patients with stable or unstable coronary disease, with similar risk of death or MI up to 4 years compared with BMS.

Place, publisher, year, edition, pages
2010. Vol. 31, no 2, 177-186 p.
Keyword [en]
Outcome, Myocardial infarction, Diabetes mellitus, Mortality, Drug-eluting stent, Percutaneous coronary intervention, Revascularization
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-53689DOI: 10.1093/eurheartj/ehp424OAI: diva2:291267
Available from: 2010-02-01 Created: 2010-02-01 Last updated: 2010-02-01

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Stenestrand, Ulf
By organisation
Cardiology Faculty of Health SciencesDepartment of Cardiology
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 38 hits
ReferencesLink to record
Permanent link

Direct link